Invivyd (IVVD) announced that it has commenced an underwritten public offering of shares of its common stock. Invivyd intends to use the net proceeds that it will receive from the offering, together with its existing cash and cash equivalents, for trial protocol development, planning and advancement of the VYD2311 clinical program, research and development related to its pipeline programs such as respiratory syncytial virus and measles, advancement of the Spike Protein Elimination and Recovery, SPEAR, Study Group efforts related to assessing the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and for working capital and other general corporate purposes. Cantor is acting as sole book-running manager for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD:
- Invivyd says PEMGARDA effective against XFG variant of SARS-CoV-2
- Invivyd’s Transformative Year: Regulatory Advances and Market Potential Drive Buy Rating
- Invivyd Aligns with FDA for Rapid Approval Pathway
- Invivyd aligns with FDA on pathway to approval of COVID-19 vaccine VYD2311
- Invivyd announces addition of Iwasaki to SPEAR Study Group